Does Retatrutide Preserve Muscle? What the Body Composition Data Shows

Introduction

Every pharmacological weight loss intervention faces the same question: how much of the weight lost is fat, and how much is lean tissue — primarily skeletal muscle? As GLP-1 receptor agonists have achieved weight loss magnitudes previously associated only with bariatric surgery, that question has taken on new urgency.

For retatrutide, which produced 28.3–28.7% average weight loss in Phase 3 trials, the muscle question is especially pertinent. Losing nearly a third of body weight inevitably involves some lean mass reduction. The question is whether retatrutide's additional efficacy comes at a disproportionate cost to muscle — and whether its glucagon receptor component, unique to this class, changes the picture.

The answer, based on the first available body composition data, is preliminary but reassuring: retatrutide's fat-to-lean mass loss ratio appears similar to semaglutide and tirzepatide. Approximately 75–80% of weight lost is fat mass, with 20–25% being lean mass. But because retatrutide produces substantially more total weight loss, the absolute amount of lean mass lost is also higher — a mathematical consequence of greater efficacy, not evidence of disproportionate muscle loss.

Phase 3 DXA data is still pending. What follows is an analysis of the Phase 2 body composition substudy published in The Lancet Diabetes & Endocrinology in June 2025, what it means for patients and clinicians, and what Phase 3 will add.

For context on retatrutide's full efficacy profile, see our comprehensive clinical results guide.

Why Lean Mass Matters in Weight Loss Treatment

Lean mass encompasses skeletal muscle, bone, water, and organ tissue. In the context of weight loss pharmacology, the primary concern is skeletal muscle. Losing excess muscle alongside fat carries real clinical consequences: reduced functional strength and mobility, lower resting metabolic rate, and heightened risk of sarcopenia — the progressive age-related decline in muscle mass that affects physical function and long-term health.

The concern is not theoretical. For a patient losing 28% of body weight on retatrutide, even a 20–25% lean component represents a meaningful absolute reduction. The clinical question is whether that reduction is proportionally different from what occurs with existing approved medications, and whether it translates into functional impairment.

Importantly, the relationship between lean mass quantity and functional capacity is not strictly linear. A modest reduction in absolute lean mass paired with a large reduction in fat mass can actually improve functional metrics — mobility, exercise tolerance, activities of daily living — because the mechanical burden of excess adiposity is reduced more than the muscular capacity to perform those activities. TRIUMPH-4's functional data supports this: participants showed a 63-meter improvement in 6-minute walk distance despite lean mass reduction, suggesting that fat loss-driven improvements in physical capacity outpaced any muscle loss effect.

The Glucagon Concern: Why This Question Is Specific to Retatrutide

Semaglutide and tirzepatide do not activate the glucagon receptor. Retatrutide does — and that distinction creates a theoretical lean mass concern that doesn't apply to existing GLP-1-class drugs.

Glucagon is a catabolic hormone. Chronic glucagon receptor activation raises concerns about lean mass because glucagon promotes gluconeogenesis — a metabolic process through which the liver synthesizes glucose using amino acids drawn from muscle tissue. If retatrutide's glucagon component drove this process chronically, the result could be disproportionate lean mass loss relative to fat mass loss.

Retatrutide's triple-agonist design was intended to mitigate this. Simultaneous GLP-1 and GIP activation suppresses glucagon's negative metabolic effects while preserving its beneficial thermogenic properties — the increased energy expenditure that contributes to retatrutide's superior weight loss versus dual agonists. Whether this theoretical mitigation holds in practice was a key question the Phase 2 DXA substudy was designed to answer.

Phase 2 DXA Data: What the Body Composition Substudy Found

A body composition substudy of the Phase 2 retatrutide trial in type 2 diabetes was published in The Lancet Diabetes & Endocrinology in June 2025. Body composition was assessed using dual-energy X-ray absorptiometry (DXA), the gold standard for distinguishing fat mass from lean mass.

The key finding: retatrutide significantly improved total body fat mass reduction compared to placebo and dulaglutide. The proportion of lean mass lost relative to total weight lost was similar to other obesity treatments. Approximately 75–80% of weight lost was fat mass, with 20–25% lean mass. The study authors concluded that these findings "could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss."

In practical terms: the glucagon concern, based on this Phase 2 data, did not materialize as disproportionate lean mass loss. The fat-to-lean ratio was in line with what has been observed with semaglutide and tirzepatide in their own body composition substudies.

Important caveats about this data:

This substudy enrolled patients with type 2 diabetes, not general obesity. Body composition response patterns can differ between these populations — patients with type 2 diabetes tend to have different baseline muscle and fat distribution profiles. The substudy covered 36 weeks of treatment. Whether the ratio holds at 68–80 weeks, as weight loss continues and decelerates, is not yet known. Phase 3 DXA data in a general obesity population is pending.

The Critical Distinction: Ratio vs. Absolute Loss

The 75–80% fat / 20–25% lean ratio is reassuring, but it requires clinical context to interpret correctly. The ratio tells you the proportional split; it does not tell you the absolute amount.

Because retatrutide produces substantially greater total weight loss than existing medications, the absolute quantity of lean mass lost will also be greater — even when the ratio is identical.

Same ratio. More absolute lean mass lost with retatrutide — not because retatrutide is worse at preserving muscle proportionally, but because the total weight loss is greater.

Whether losing 18 lbs versus 9 lbs of lean mass matters clinically depends on factors including starting muscle mass, age, exercise habits, protein intake, and the patient's primary clinical goal. For most patients, the tradeoff — an additional ~9 lbs of lean mass lost in exchange for an additional ~25 lbs of fat lost — is likely favorable. For older patients or those with pre-existing sarcopenia concerns, it warrants proactive management.

How This Compares to Tirzepatide and Semaglutide

Available DXA data from semaglutide and tirzepatide trials shows fat-to-lean ratios in a similar range — generally 70–80% fat / 20–30% lean — consistent with the retatrutide Phase 2 finding.

This consistency across drug classes is notable. Despite meaningfully different mechanisms (single, dual, and triple agonism), the body's proportional response to pharmacological appetite suppression appears similar. The ratio that applies to semaglutide at 15% weight loss appears to apply to retatrutide at 28%. What differs is the magnitude of the total loss, and therefore the absolute quantity on both sides of the ratio.

No head-to-head DXA comparison between retatrutide and tirzepatide exists. The available data comes from separate trials with different populations, durations, and methodologies. Cross-trial comparisons of absolute numbers carry the usual caveats of indirect comparison.

For the complete weight loss efficacy comparison, see our retatrutide vs tirzepatide vs semaglutide comparison.

What Phase 3 Will Tell Us

The Phase 2 DXA substudy has two important limitations that Phase 3 data will address.

First, the population: it enrolled patients with type 2 diabetes, not general obesity. The TRIUMPH obesity trials enroll a different population with different baseline characteristics. Whether the 75–80% fat ratio holds in general obesity patients losing 28% of body weight over 68–80 weeks is the key open question.

Second, the duration: 36 weeks is substantially shorter than TRIUMPH-1's 80-week endpoint or TRIUMPH-4's 68-week endpoint. It is plausible that as the rate of weight loss decelerates in later treatment phases, the proportion of lean mass in that loss shifts — potentially improving (more fat, less lean) as the body adapts. Longer-duration DXA data would address this.

Per the published TRIUMPH program design paper (Giblin et al., Diabetes, Obesity and Metabolism, 2026), TRIUMPH-3 — the obesity plus cardiovascular disease trial — includes a DXA substudy in approximately 100 participants to assess percent and absolute change in total body fat and lean mass. TRIUMPH-3 results are expected later in 2026. The DXA substudy data may be reported alongside primary results or as a separate publication.

Practical Implications for Patients

Based on currently available data, patients and clinicians should expect the following when retatrutide becomes available:

The fat-to-lean ratio will likely resemble existing GLP-1 medications. The Phase 2 reassurance on this point is meaningful — it suggests the glucagon receptor component does not fundamentally alter the body's compositional response to weight loss at the doses studied.

Absolute lean mass loss will be higher than with semaglutide or tirzepatide because total weight loss is higher. For a patient losing 70 lbs versus 35 lbs, this is an unavoidable arithmetic consequence.

Resistance training is the most evidence-based intervention for attenuating lean mass loss during any weight loss treatment, pharmacological or otherwise. All TRIUMPH trials include individualized lifestyle counseling with emphasis on physical activity, and dietary guidance focuses on maintaining a macronutrient-balanced diet with adequate protein intake. Patients considering retatrutide should treat resistance training and protein adequacy as part of the treatment protocol, not optional additions.

For patients with pre-existing sarcopenia, advanced age, or low muscle mass, the absolute lean mass numbers — and a proactive plan to address them — merit explicit clinical attention before and during treatment.

Conclusion

The first peer-reviewed body composition data for retatrutide, from a Phase 2 DXA substudy published in The Lancet Diabetes & Endocrinology in June 2025, provides preliminary but meaningful reassurance: the proportion of weight lost as lean mass is approximately 20–25%, consistent with semaglutide and tirzepatide. The theoretical concern that retatrutide's glucagon receptor activation would disproportionately increase lean mass loss did not materialize in Phase 2 data.

The important nuance is the absolute vs. ratio distinction. Retatrutide's superior total weight loss means greater absolute lean mass lost in numerical terms, even when the ratio is identical to less efficacious drugs. For most patients, that tradeoff is clinically favorable — but it warrants individualized assessment, particularly in older patients or those with lower baseline muscle mass.

Phase 3 DXA data from TRIUMPH-3 (~100 participants) will provide the next piece of evidence. Until then, the Phase 2 data supports cautious optimism: retatrutide does not appear to preferentially sacrifice muscle over fat.

Sources

• Phase 2 body composition substudy: "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial." The Lancet Diabetes & Endocrinology. June 2025.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023;389:514–526.
• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.